Enovis (NYSE:ENOV) Stock Rating Lowered by Wall Street Zen

Enovis (NYSE:ENOV) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Sunday, Wall Street Zen reports.

A number of other equities analysts have also weighed in on the company. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. UBS Group restated a “buy” rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Evercore set a $32.00 target price on Enovis in a report on Monday, July 6th. BTIG Research dropped their target price on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Finally, BMO Capital Markets set a $27.00 price target on Enovis in a research report on Tuesday, September 1st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Enovis Stock Down 0.4%

ENOV stock opened at $17.96 on Friday. The company has a market capitalization of $1.04 billion, a P/E ratio of -0.93 and a beta of 1.31. Enovis has a 12 month low of $17.30 and a 12 month high of $34.28. The firm’s fifty day simple moving average is $24.38 and its 200-day simple moving average is $23.84. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis will post 3.15 earnings per share for the current year.

Insider Activity

In other Enovis news, CEO Damien Mcdonald purchased 13,035 shares of the stock in a transaction on Friday, September 4th. The shares were bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Oliver Engert acquired 5,140 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the acquisition, the insider owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 23,293 shares of company stock valued at $449,599. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC acquired a new stake in Enovis in the 2nd quarter valued at $39,000. IFP Advisors Inc lifted its holdings in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares in the last quarter. Allworth Financial LP lifted its holdings in Enovis by 59.7% during the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock valued at $36,000 after purchasing an additional 652 shares in the last quarter. Amundi grew its position in shares of Enovis by 397.7% in the second quarter. Amundi now owns 369,189 shares of the company’s stock valued at $7,642,000 after purchasing an additional 295,005 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Enovis in the second quarter valued at about $559,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.